indication directory

Type 2 Diabetes clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT03037099

Source recordAI-normalized

Enhancing Glycemic Index Knowledge and Application Among Adults With Type-2 Diabetes Mellitus

The HEALD-GI study, sponsored by Athabasca University, aims to enhance dietary education focused on the Glycemic Index for adults with Type 2 Diabetes Mellitus (T2DM). With a growing global prevalence of diabetes, effective dietary management strategies are critical. This study's findings could inform future dietary interventions and educational programs, potentially leading to improved patient outcomes and reduced healthcare costs. The results may also position Athabasca University and its collaborators as leaders in diabetes management research, opening avenues for partnerships with healthcare providers and nutrition-focused organizations. The competitive landscape includes other diabetes education programs, but HEALD-GI's focus on GI may provide a unique selling proposition.

AI analysis

Indication: Type 2 Diabetes

Modality: behavioral intervention

Target: Glycemic Index (GI) dietary education and its impact on dietary behavior and glycemic control in adults with Type 2 Diabetes Mellitus.

Sponsor: Athabasca University

Source URL: ClinicalTrials.gov

Source updated: Jul 10, 2018

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Type 2 Diabetes

View original source fields

Condition raw: Type 2 Diabetes

Condition normalized: Type 2 Diabetes

Modality raw: behavioral intervention

Modality normalized: behavioral intervention

Target raw: Glycemic Index (GI) dietary education and its impact on dietary behavior and glycemic control in adults with Type 2 Diabetes Mellitus.

Target normalized: Glycemic Index (GI) dietary education and its impact on dietary behavior and glycemic control in adults with Type 2 Diabetes Mellitus.

Open report

NCT03194009

Source recordAI-normalized

Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.

The PRuDENTE initiative, sponsored by the Instituto Nacional de Salud Publica in Mexico, aims to evaluate the cost-effectiveness of metformin combined with lifestyle modifications in preventing type 2 diabetes among pre-diabetic adults with obesity. Given the high prevalence of diabetes in Mexico, this study addresses a significant public health challenge and has the potential to inform national healthcare policies. If successful, the findings could lead to broader adoption of metformin as a preventive measure, impacting the pharmaceutical market for diabetes medications and lifestyle interventions. The study's outcomes may also attract interest from healthcare providers and insurers focused on cost-effective diabetes prevention strategies.

AI analysis

Indication: Diabetes Mellitus, Type 2

Modality: small molecule

Target: Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Sponsor: Instituto Nacional de Salud Publica, Mexico

Source URL: ClinicalTrials.gov

Source updated: Mar 07, 2018

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Diabetes Mellitus, Type 2

View original source fields

Condition raw: Diabetes Mellitus, Type 2, Prediabetic State

Condition normalized: Diabetes Mellitus, Type 2, Prediabetic State

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Target normalized: Metformin's mechanism of action primarily involves the reduction of hepatic glucose production, increased insulin sensitivity, and improved peripheral glucose uptake, making it a suitable intervention for pre-diabetes and type 2 diabetes management.

Open report

NCT06641765

Source recordAI-normalized

Continuous Glucose Monitoring in Haemodialysis and Peritoneal Dialysis Patients With Type 1 and Type 2 Diabetes

The primary objective of this multicenter, randomized controlled trial is to assess whether the intermittent or continuous use of continous glucose monitoring can enhance glycaemic control among dialysis patients with type 1 or type 2 diabetes, in comparison to the standard monitoring involving finger-prick glucose and HbA1c. Participants will be monitored for 9 months and randomly assigned to one of three groups: * Group 1, the control group, will undergo standard monitoring (using HbA1c and BGM) along with double-blinded CGM sessions at month 0, 3, 6, and 9. * Group 2 will have intermittent access to open CGM during the same time intervals. * Group 3 will have continuous access to open CGM throughout the entire duration of the study. During the study period, participants will have three consultations with an endocrinologist for adjustments in their glucose-lowering treatment. The goal is to compare markers of glycaemic control between the three groups. Secondary objectives include evaluating the impact on hypoglycaemia, quality of life, hospitals admissions and cardiovascular events.

AI analysis

Indication: Diabetes Mellitus, Type 2

Modality: medical device

Target: Continous Glucose Monitoring

Sponsor: Bo Feldt-Rasmussen

Source URL: ClinicalTrials.gov

Source updated: Feb 27, 2026

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Diabetes Mellitus, Type 2

View original source fields

Condition raw: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Continuous Glucose Monitoring, Haemodialysis, Peritoneal Dialysis

Condition normalized: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Continuous Glucose Monitoring, Haemodialysis, Peritoneal Dialysis

Modality raw: medical device

Modality normalized: medical device

Target raw: Continous Glucose Monitoring

Target normalized: Continous Glucose Monitoring

Open report

NCT06895018

Source recordAI-normalized

Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects with Type 2 Diabetes

The study, sponsored by Federico II University, investigates the effects of a polyphenol-rich beverage derived from red grape pomace on non-alcoholic fatty liver disease (NAFLD) and related metabolic conditions in patients with type 2 diabetes. Given the rising prevalence of NAFLD and the absence of pharmacological treatments, this asset addresses a significant unmet medical need. The potential for dietary polyphenols to improve liver health and metabolic profiles could position this beverage favorably in the dietary supplement market, particularly among diabetic and obese populations. The competitive landscape includes other dietary interventions and emerging pharmacotherapies for NAFLD, necessitating a thorough market analysis and strategic positioning. Diligence should focus on regulatory pathways, especially concerning health claims and market entry strategies.

AI analysis

Indication: Diabetes Mellitus Type 2

Modality: RNA therapy

Target: Polyphenol metabolites and their phase II derivatives impacting hepatic steatosis, cardiometabolic risk, and gut microbiota composition.

Sponsor: Federico II University

Source URL: ClinicalTrials.gov

Source updated: Mar 26, 2025

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Diabetes Mellitus Type 2

View original source fields

Condition raw: Diabetes Mellitus Type 2

Condition normalized: Diabetes Mellitus Type 2

Modality raw: RNA therapy

Modality normalized: RNA therapy

Target raw: Polyphenol metabolites and their phase II derivatives impacting hepatic steatosis, cardiometabolic risk, and gut microbiota composition.

Target normalized: Polyphenol metabolites and their phase II derivatives impacting hepatic steatosis, cardiometabolic risk, and gut microbiota composition.

Open report

NCT06529965

Source recordAI-normalized

Evaluating a Digital Intervention for Alleviating Diabetes-specific Emotional Distress in Adults Living With Type 2 Diabetes Mellitus: Randomized Controlled Trial

Gaia AG's covivio is positioned within the growing digital health market, specifically targeting the management of emotional distress in adults with Type 2 Diabetes Mellitus (T2DM). The trial's focus on emotional well-being complements traditional diabetes management, potentially enhancing patient adherence and overall treatment outcomes. Given the increasing prevalence of T2DM and the associated psychological burden, successful results could lead to significant market opportunities. The competitive landscape includes other digital therapeutics and mental health applications, necessitating a robust differentiation strategy. Diligence should focus on regulatory pathways, reimbursement models, and integration with existing diabetes care frameworks.

AI analysis

Indication: Glucose Metabolism Disorders (Including Diabetes Mellitus)

Modality: behavioral intervention

Target: Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Sponsor: Gaia AG

Source URL: ClinicalTrials.gov

Source updated: Nov 08, 2024

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Diabetes Mellitus, Type 2

View original source fields

Condition raw: Glucose Metabolism Disorders (Including Diabetes Mellitus), Metabolic Disease, Endocrine System Diseases, Diabetes Mellitus, Type 2

Condition normalized: Glucose Metabolism Disorders (Including Diabetes Mellitus), Metabolic Disease, Endocrine System Diseases, Diabetes Mellitus, Type 2

Modality raw: behavioral intervention

Modality normalized: behavioral intervention

Target raw: Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Target normalized: Digital therapeutic intervention aimed at alleviating diabetes-specific emotional distress through cognitive behavioral therapy (CBT) techniques.

Open report